20:45 , Nov 6, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer, pancreatic cancer Patient sample and mouse studies suggest combining DNA-PK inhibitors with the oncolytic alphavirus M1 could help treat colorectal and pancreatic cancers. In colorectal tumor cells from patients, a DNA-PK inhibitor...
19:23 , Jun 20, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Gene therapy A four-compound cocktail could enhance the efficiency of CRISPR-based editing in pluripotent stem cells. The method involves CRISPR-based editing in pluripotent stem cells with systems based on CRISPR from Prevotella and Francisella...
17:09 , Jun 15, 2017 |  BC Week In Review  |  Clinical News

Merck reports Phase Ia data for DNA-PK inhibitor M3814 in solid tumors

Merck KGaA (Xetra:MRK) reported data from 7 evaluable patients with advanced solid tumors or metastases including lymphoma localized in the head and neck region or thorax in the Phase Ia portion of a Phase Ia/Ib...
02:31 , Jun 15, 2017 |  BC Week In Review  |  Clinical News

Merck reports Phase I data for DNA-PK inhibitor M3814 in solid tumors

Merck KGaA (Xetra:MRK) reported data from 25 evaluable patients with advanced solid tumors in a Phase I trial showing that oral M3814 (MSC 2490484A) led to 6 cases of stable disease lasting for ≥18 weeks....
16:15 , Jan 13, 2017 |  BC Week In Review  |  Company News

Vertex, Merck deal

Vertex granted Merck exclusive, worldwide rights to four cancer programs. Vertex will receive $230 million up front and is eligible for royalties. Merck will be responsible for the programs' development and commercialization. The deal includes...
00:17 , Jan 12, 2017 |  BC Extra  |  Company News

Vertex grants Merck KGaA rights to cancer programs

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) granted Merck KGaA (Xetra:MRK) exclusive, worldwide rights to four cancer programs. Vertex is to receive $230 million up front and is eligible for royalties. Merck will be responsible for the programs'...
07:00 , Jun 13, 2016 |  BC Week In Review  |  Clinical News

CC-115: Phase I data

Top-line data from 82 evaluable patients with relapsed or refractory advanced solid tumors and hematological malignancies in a 2-part, open-label, international Phase Ia/Ib trial showed that oral CC-115 led to 1 complete response in a...
07:00 , Jul 25, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Ataxia telangiectasia mutated (ATM); DNA-dependent protein kinase (DNA-PK) Mouse and cell culture studies suggest inhibiting the DNA-PK catalytic subunit could help treat ATM-deficient cancers....
07:00 , May 24, 2012 |  BC Innovations  |  Targets & Mechanisms

Getting selective for gamma

Cellzome AG and Exelixis Inc. have independently designed the first highly selective inhibitors of the g-isoform of phosphoinositide 3-kinase . 1,2 Exelixis plans to out-license its inhibitors, whereas last week's acquisition of Cellzome by GlaxoSmithKline...
07:00 , Jun 1, 2009 |  BC Week In Review  |  Company News

AstraZeneca, Cancer Research UK, University of Newcastle deal

AstraZeneca's KuDos Pharmaceuticals Ltd. subsidiary exercised a 2004 option for exclusive, worldwide rights to a portfolio of DNA-dependent protein kinase (DNA-PK) inhibitors jointly owned by the university and Cancer Research UK 's Cancer Research Technology...